Why the study?
Does renin-angiotensin-aldosterone system inhibition improve renal and cardiovascular outcomes in patients with chronic kidney disease?
Population
Patients with chronic kidney disease (CKD)
Design
Review
Authors
Loading...
Supports RAAS inhibition in CKD for renal/CV protection; leaves open optimal combinations and dosing in advanced stages.
Does renin-angiotensin-aldosterone system inhibition improve renal and cardiovascular outcomes in patients with chronic kidney disease?
RAAS inhibition with ACEIs and ARBs provides significant renal and cardioprotection in patients with chronic kidney disease.
Norris et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: